Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ESPERION THERAPEUTICS INC Create: Alert

All | News | Filings
Date FiledTypeDescription
02/10/2022 SC 13G PLATINUM INVESTMENT MANAGEMENT LTD has filed a Schedule 13D for Esperion Therapeutics, Inc.
05/27/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2020 SC 13G/A Boxer Capital, LLC reports a 3.6% stake in ESPERION THERAPEUTICS, INC.
02/14/2019 SC 13G/A Boxer Capital, LLC reports a 6.6% stake in ESPERION THERAPEUTICS, INC.
02/13/2019 SC 13G/A BB BIOTECH AG reports a 12.7% stake in ESPERION THERAPEUTICS, INC.
02/14/2018 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2017 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2017 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend]
07/26/2004 SC 13D/A Form SC 13D - General statement of acquisition of beneficial ownership [amend]
02/17/2004 SC 13G/A ESPERION THERAPEUTICS INC reports a 12.7% stake in Esperion Therapeutics Incorporated
02/13/2004 SC 13G/A ESPERION THERAPEUTICS INC reports a 0% stake in Esperion Therapeutics Inc.
02/11/2004 8-K Quarterly results
01/23/2004 8-K Quarterly results
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED DECEMBER 31, 2003"
01/16/2004 SC 13D/A Form SC 13D - General statement of acquisition of beneficial ownership [amend]
12/23/2003 8-K Other events, Financial statements and exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer Inc., Enzo",
"Amendment No. 3, to the Rights Agreement, between Esperion Therapeutics, Inc",
"Amendment, to Collaboration and License Agreement, between Esperion"
11/10/2003 10-Q Quarterly Report for the period ended September 30, 2003
11/10/2003 SC 13G ESPERION THERAPEUTICS INC reports a 10.6% stake in Esperion Therapeutics Incorporated
10/30/2003 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership
10/28/2003 10-Q/A Quarterly Report for the period ended June 30, 2003 [amend]
10/20/2003 8-K Quarterly results
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2003"
08/14/2003 10-Q Quarterly Report for the period ended June 30, 2003
08/01/2003 SC 13D/A Form SC 13D - General statement of acquisition of beneficial ownership [amend]
07/29/2003 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership
07/29/2003 8-K Other events, Financial statements and exhibits
Docs: "EXHIBIT NO. EXHIBIT DESCRIPTION",
"Amendment No. 2 to Rights Agreement, between Esperion Therapeutics, Inc. and StockTrans, Inc., as Rights Agent",
"Voting and Transfer Restriction Agreement by and among Esperion Therapeutics, Inc., Scott Sacane, Durus Capital Management, LLC and Durus Capital Management (NA), LLC"
07/16/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
05/14/2003 10-Q Quarterly Report for the period ended March 31, 2003
04/30/2003 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2003"
03/26/2003 10-K Annual Report for the period ended December 31, 2002
02/13/2003 SC 13G/A Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend]
11/26/2002 8-K Other events, Financial statements and exhibits
Docs: "EXHIBIT NO. EXHIBIT DESCRIPTION",
"Amendment No. 1 to Rights Agreement, between Esperion Therapeutics, Inc. and StockTrans, Inc., as Rights Agent"
11/14/2002 10-Q Quarterly Report for the period ended September 30, 2002
11/08/2002 SC 13G/A Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend]
08/14/2002 10-Q Quarterly Report for the period ended June 30, 2002
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy